The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II).
Publication/Presentation Date
6-1-2017
Abstract
OBJECTIVE: To offer recommendations on identification of disease progression, treatment management strategies, and suggestions on timing of initiating and discontinuing specific castration-resistant prostate cancer (CRPC) treatments.
MATERIALS AND METHODS: The Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II Working Group convened to provide guidance on sequencing, combination, or layering of approved treatments for metastatic CRPC based on available data and clinical experience.
RESULTS: A consensus was developed to address important questions on management of patients with metastatic CRPC.
CONCLUSION: In the absence of large-scale clinical trials, the Working Group recommends that patients may best be managed with a layered approach of approved therapies with unique or complimentary mechanisms of action.
Volume
104
First Page
150
Last Page
159
ISSN
1527-9995
Published In/Presented At
Crawford, E. D., Petrylak, D. P., Shore, N., Saad, F., Slovin, S. F., Vogelzang, N. J., Keane, T. E., Koo, P. J., Gomella, L. G., O'Sullivan, J. M., Tombal, B., Concepcion, R. S., Sieber, P., Stone, N. N., Finkelstein, S. E., Yu, E. Y., & Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR II) Group (2017). The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology, 104, 150–159. https://doi.org/10.1016/j.urology.2016.12.033
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
28302580
Department(s)
Administration and Leadership
Document Type
Article